FDA Approves Vepdegestrant (VEPPANU): The World's First PROTAC Cancer Drug — What It Means for Breast Cancer Patients Worldwide
On May 1, 2026, the FDA approved vepdegestrant (VEPPANU), the first-ever PROTAC protein degrader for ER+/HER2-/ESR1-muta...
Read More →